ODAC votes to keep Keytruda and Tecentriq accelerated approvals in bladder cancer
The FDA’s Oncologic Drugs Advisory Committee is continuing to find it difficult to say no to cancer patients, especially as bladder cancer patients affected by …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
